ObsEva
Closed portfolio snapshot
According to ClinicalTrials.gov-derived indexes, ObsEva sits in the upper quartile of US sponsors by registered trial count (#2,411 of 15,742 sponsors by registered trial count).
ObsEva: 5 sponsored US clinical trials, none currently recruiting.
ObsEva sponsors 5 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 5 completed. 2 of these trials are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Heavy Menstrual Bleeding, with 1 trials.
Upper-quartile sponsor footprint
ObsEva sits in the upper quartile of the sponsor corpus (#2,411 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Indexed trials (enrollment closed)
5 total, page 1 of 1
Safety and Pharmacokinetics Study of Linzagolix in Female Subjects With Normal and Impaired Hepatic Function
NCT03962049
Safety and Pharmacokinetics of Linzagolix in Female Subjects With Normal and Impaired Renal Function
NCT03961932
Efficacy and Safety of OBE2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids
NCT03070951
Efficacy and Safety of OBE2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids
NCT03070899
A Study to Assess the Efficacy and Safety of OBE2109 in Subjects With Endometriosis
NCT02778399
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 1 |
| Phase 3 | 2 |
Therapeutic Areas
How the ObsEva archive is shaped
5 indexed studies, none listed as recruiting (0% open); 5 completed (100%).
Phase mix: 2 late (III/IV) vs 3 early (I/II) (balanced across stages).
Top condition: Heavy Menstrual Bleeding (1 trial), 1 other listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
ObsEva: archived-pipeline peers nationwide
Peers matched on 5 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
ObsEva sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 5 archived trials
- 4YouandMe · 5 trials · 0% recruiting
- Abbott Rapid Dx · 5 trials · 0% recruiting
- Access Business Group · 5 trials · 0% recruiting
- Acera Surgical · 5 trials · 20% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this ObsEva page
5 registered trials is a research-attention snapshot, not an endorsement of ObsEva or any single study.
- None of ObsEva's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Heavy Menstrual Bleeding is the condition ObsEva studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Heavy Menstrual Bleeding trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
ObsEva pipeline card: 5 registered trials from official public datasets.Report a data error.